EpiAxis Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
EpiAxis Therapeutics General Information
Description
Developer of small-molecule therapeutics intended for the treatment of advanced cancers. The company pursues a preclinical and clinical drug development program directed at the prevention of metastatic cancer by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells, enabling the medical industry to prevent metastatic breast cancer, with other mediated diseases such as ovarian, pancreatic, colon, melanoma, lung, and liver cancers.
Contact Information
Website
www.epiaxistherapeutics.comCorporate Office
- Bruce
- Canberra, Australian Capital Territory 2617
- Australia
Corporate Office
- Bruce
- Canberra, Australian Capital Territory 2617
- Australia
EpiAxis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 2. Later Stage VC | 24-Feb-2022 | Completed | Generating Revenue | |||
| 1. Angel (individual) | Completed | Startup |
EpiAxis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
EpiAxis Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EpiAxis Therapeutics Patents
EpiAxis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021903498-A0 | Proteinaceous molecules and uses therefor | Pending | 02-Nov-2021 | ||
| WO-2023077188-A1 | Proteinaceous molecules and uses therefor | Inactive | 02-Nov-2021 | ||
| AU-2020902961-A0 | Inhibitors and uses therefor | Pending | 19-Aug-2020 | ||
| AU-2020227319-A1 | Methods and agents for assessing t-cell function and predicting response to therapy | Active | 27-Feb-2019 | ||
| AU-2020227319-B2 | Methods and agents for assessing t-cell function and predicting response to therapy | Active | 27-Feb-2019 | G01N33/5091 |
EpiAxis Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EpiAxis Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Artesian | Venture Capital | Minority | ||
| Proto Investment Partners | Angel Group | Minority | ||
| Sydney Angels | Angel Group | Minority |
EpiAxis Therapeutics FAQs
-
When was EpiAxis Therapeutics founded?
EpiAxis Therapeutics was founded in 2015.
-
Where is EpiAxis Therapeutics headquartered?
EpiAxis Therapeutics is headquartered in Canberra, Australia.
-
What is the size of EpiAxis Therapeutics?
EpiAxis Therapeutics has 6 total employees.
-
What industry is EpiAxis Therapeutics in?
EpiAxis Therapeutics’s primary industry is Biotechnology.
-
Is EpiAxis Therapeutics a private or public company?
EpiAxis Therapeutics is a Private company.
-
What is EpiAxis Therapeutics’s current revenue?
The current revenue for EpiAxis Therapeutics is .
-
How much funding has EpiAxis Therapeutics raised over time?
EpiAxis Therapeutics has raised $4.73M.
-
Who are EpiAxis Therapeutics’s investors?
Artesian, Proto Investment Partners, and Sydney Angels have invested in EpiAxis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
